Viewing Study NCT04546256


Ignite Creation Date: 2025-12-24 @ 11:19 PM
Ignite Modification Date: 2026-05-22 @ 2:53 PM
Study NCT ID: NCT04546256
Status: COMPLETED
Last Update Posted: 2021-03-09
First Post: 2020-09-06
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUSĀ® 500/50 Inhalation Powder/GSK in Healthy Volunteers
Sponsor: Respirent Pharmaceuticals Co Ltd.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Bioequivalence View
Keywords:

Keywords

Keyword Brief Keyword Text View
None bioequivalence View
None fluticasone propionate View
None salmeterol xinafoate View
None ADVAIR View